Twist Bioscience (TWST) Form 4: RSU Sell-to-Cover Reported at $25.328

Rhea-AI Filing Summary

Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp (TWST), reported a non-discretionary sale of shares on 09/15/2025 to satisfy tax withholding tied to vested restricted stock units. The reported transaction lists a price of $25.328 per share and shows 102,943 shares beneficially owned by the reporting person after the transaction. The filing was signed by an attorney-in-fact on 09/17/2025. The form states the sale was a mandated "sell to cover" required by the issuer's equity incentive plan and not a discretionary trade by the reporting person.

Positive

• Transaction explicitly identified as non-discretionary sell-to-cover tied to RSU vesting, clarifying the nature of the sale
• Post-transaction beneficial ownership disclosed as 102,943 shares, maintaining transparency on insider holdings

Negative

• Insider disposition reported (sell-to-cover), which reduces insider-held shares even if non-discretionary

Insights

Corporate Governance Expert

TL;DR Routine, non-discretionary sell-to-cover of RSUs by a senior officer; no indication of voluntary cashing out.

The Form 4 documents a mandated sale to satisfy tax withholding on vested restricted stock units for a named officer. Because the filing explicitly states the transaction was a sell-to-cover required under the issuer's equity plan, this is a common administrative event that does not necessarily signal a change in the officer's view of the company. The post-transaction beneficial ownership of 102,943 shares remains disclosed, preserving transparency on insider holdings. No additional governance or related-party issues are disclosed in the filing.

Securities Analyst

TL;DR Insider sold shares at $25.328 as a tax-withholding action; transaction appears administrative and not material to valuation.

The filing records a sale occurring on 09/15/2025 at a reported price of $25.328 per share described as a sell-to-cover tied to RSU vesting. Such transactions typically reduce an insider's gross share count without indicating portfolio reallocation or liquidity-driven selling. The remaining direct beneficial ownership is reported as 102,943 shares, which continues to provide the market with a snapshot of insider exposure. No derivative transactions or other compensatory arrangements are reported beyond the described withholding sale.

Insider Trade Summary

Net Seller: 94 shares ($2,381)

Net Sell 1 txn

Insider Cho Dennis

Role See Remarks

Sold 94 shs ($2K)

Type	Security	Shares	Price	Value
Sale	Common Stock	94	$25.328	$2K

Holdings After Transaction: Common Stock — 102,943 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Cho Dennis

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2025		S		94(1)	D	$25.328	102,943	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

Senior Vice President, Chief Legal Officer & Corporate Secretary

	/s/ Kendra Fox, as Attorney-in-Fact for Dennis Cho	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Dennis Cho report on the Form 4 for TWST?

The form reports a sell-to-cover transaction tied to RSU vesting on 09/15/2025, with a reported price of $25.328 per share and 102,943 shares beneficially owned after the transaction.

Was the sale by the TWST reporting person discretionary?

No; the filing explicitly states the sale was mandated by the issuer's equity incentive plan as a tax withholding sell-to-cover and did not represent a discretionary trade.

What is the reporting person’s title at Twist Bioscience (TWST)?

The filing lists the reporting person as Senior Vice President, Chief Legal Officer & Corporate Secretary.

When was the Form 4 signed and by whom?

The filing was signed by Kendra Fox as attorney-in-fact for Dennis Cho on 09/17/2025.

How many shares does the reporting person beneficially own after the transaction?

The Form 4 reports 102,943 shares beneficially owned following the reported transaction.